← Back

Pulmatrix Inc

Pulmatrix, Inc., a biopharmaceutical company, focused on development of novel inhaled therapeutic products to prevent and treat migraine and respiratory diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor compounds. The company was founded in 2003 and is headquartered in Framingham, Massachusetts.

Price · split & dividend adjusted
News & notes moving PULM
PULM

Halper Sadeh LLC Investigates SLP, HUN, OLN, PULM Deals for Shareholder Fairness

Halper Sadeh LLC, an investor rights law firm, is investigating Simulations Plus, Huntsman Corporation, Olin Corporation, and Pulmatrix for potential violations of federal securities laws or breaches of fiduciary duties in their proposed transactions. The investigations cover Simulations Plus's sale to Altaris affiliates for $18.50 per share, Huntsman's sale to Olin for 0.5476 Olin shares per Huntsman share, Olin's merger with Huntsman where Olin shareholders would own about 54.5% of the combined company, and Pulmatrix's merger with Eos SENOLYTIX where Pulmatrix stockholders would own about 6% of the combined company. The firm may seek increased consideration, additional disclosures, or other relief on behalf of shareholders.
GlobeNewswire·47dRead more ▾